Chlamydia pneumoniae, a Gram-negative intracellular obligate bacteria, is recognised as a common cause of upper respiratory tract infections, and accounts for~10% of community-acquired pneumonia (l). C. pneumoniae has a unique developmental cycle with two alternating functional and morphological forms: the elementary body (EB) and the reticulate body (RB). The EB is the metabolically inert, infectious form of the organism that is capable of transient extracellular survival. The RB is the intracellular replicate form of the organism but not infectious. The normal cycle may be disrupted by the induction of persistence as a result of nutritional deprivation, antibiotic treatment or growth in monocytes/macrophages and the appearance of large aberrant bacterial forms (2) . Reactivation of the normal developmental cycle can be observed when the inducer of persistence is removed. Intracellular persistent forms of the C. pneumoniae are inherently more suited to chronic infections and are more difficult to eradicate by antibiotics (2) .
In recent years, chronic and persistent infection with C. pneumoniae has been implicated in the pathogenesis of chronic diseases such as multiple sclerosis (3), Alzheimer's disease (4) and atherosclerosis (2) . The most significant evidence in the last decade has been the recognition that C. pneumoniae is associated with atherosclerosis (2). Atherosclerosis is regarded as a chronic inflammatory disease that results from complex interactions between a variety of cell types such as endothelial cells, vascular smooth muscle cells, monocytes/macrophages and inflammatory mediators.
Involvement of C. pneumoniae In the pathogenesis of atherosclerosis has been supported by findings from seroepidemiologic studies, direct detection of chlamydial DNA, experimental animal and in vitro studies, and antibiotic intervention trials (Fig.I ). The first suggestion that C. pn eumoniae may be associated with atherosclerosis was proposed in 1988 by Saikku et al. (5) . They showed that patients with acute myocardial infarction and chronic heart diseases had anti-C. pneumoniae antibody more frequently than population controls . Since then, several studies have confirmed the association between serological evidence of C. pneumoniae infection and atherosclerotic cardiovascular diseases (6) (7) (8) . In addition, findings exist regarding the relation between C. pneumoniae serology and traditional risk factors for atherosclerotic cardiovascular diseases such as smoking, dyslipidemia and hypertension (6, (9) (10) . Recently, prospective serologic studies (11-12) , however, failed to demonstrate this association since a large part of the population has pre-existing IgG antibodies from previous exposure(s) and, hence, it is difficult to identify differences in seropositivity between patients and controls. However, measurement of immune responses to specific chlamydial antigens such as 60-kDa Heat Shock Protein (HSP-60) has provided more convincing seroepidemiological data to implicate the possibility that exposure to chlamydiaI GroELl represents an independent risk factor for coronary atherosclerosis and disease development (13) . Further evidence that C. pneumoniae might play a role in atherogenesis came from studies that identified C. pneumoniae in the atherosclerotic lesions by immunohistochemistry (ICC), electron microscopy (EM), amplification of chlamydial DNA by polymerase chain reaction (PCR) and culture (7) . In 1992, Shor et al. (14) were the first to identify C. pn eumoniae by EM and ICC in atherosclerotic coronary plaques. So far a large number of studies (7, (15) (16) (17) have been published on the detection of C. pneumoniae in vascular tissue by PCR. However, the frequency of positive results varies considerably (from 0 to 100%) among the studies because no standardized PCR assays are available yet.
The association of C. pneumoniae and atherosclerotic cardiovascular disease has been strengthened by studies in animal models and in vitro. In animal models, repeated infection with C. pn eumoniae through the respiratory tract demonstrates induction of early atherosclerotic lesions or accelerated progression of atherosclerosis in the aorta (18) . Furthermore , results from studies in both rabbit and mice indicate that C. pneumoniae may exacerbate atheromatous lesions associated with hyperlipidemia suggesting that these two risk factors may interact or have a synergistic effect in atherogenesis (19) (20) .
In vitro studies have shown that C. pneumoniae can infect monocytes/macrophages, endothelial and smooth muscle cells, and can induce macrophage foam cell formation (21) (22) . The multiplication of C. pneumoniae inside monocytes or macrophages triggers the production of pro-inflammatory cytokines (interleukin-l, interleukin-6, tumornecrosis factor-a); the infection of endothelial cells by C. pneumoniae induces expression of adhesion molecules (endothelial-leukocyte adhesion molecule I, intercellular adhesion molecule I and vascular cell adhesion molecule), and stimulates transendothelial migration of neutrophils and monocytes (23) (24) . These studies suggested that C. pneumoniae disseminates systemically from the lungs through infected peripheral blood mononuclear cells and localizes in arteries where it infects cells of the vascular wall involved in the atherogenic process.
As well as in vitro studies, confirmation that C. pneumoniae-infected peripheral blood mononuclear cells can be found in vivo has also been reported (16, (25) (26) (27) . The evidence linking C. pneumoniae infection with atherosclerosis has led to several therapeutic intervention trials in patients with established coronary heart disease (28) . Results of preliminary studies were encouraging, but larger and longer prospective antibiotic treatment trials under way may provide better insight into the association of C. pneumoniae with atherosclerotic cardiovascular disease. In conclusion the spectrum of cell biological, animal, and human clinical data suggest that C. pneumoniae may be considered an infectious risk factor for atherosclerosis but further studies are needed to clarify the etiopathogenetic role of C. pneumoniae in atherosclerotic vessel walls.
